FDA approves tarlatamab for ES-SCLC

Thursday, 16 May 2024 | Lung Cancer

On May 16, 2024, the Food and Drug Administration (FDA) gave accelerated approval to Imdelltra (tarlatamab-dlle), developed by Amgen, Inc., for treating extensive stage small cell lung cancer (ES-SCLC) that has progressed despite platinum-based chemotherapy.

To continue, please login or sign up first